Physician profile
Jeffrey B Stricker
NPI 1013973692
$10,410.36
in general payments reported to CMS, 2019-2025
28 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $812 · 2021: $1,544 · 2022: $2,157 · 2023: $1,934 · 2024: $1,859 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,682.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,309.81 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,583.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,099.54 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $925.75 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $771.62 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $737.16 | 2019-2025 | |
| Lilly USA, LLC | $505.46 | 2019-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $450.80 | 2020-2025 | Blu-U, Ilumya |
| Leo Pharma INC. | $391.90 | 2019-2025 | Adbry |
| Organogenesis INC. | $349.73 | 2022-2025 | Puraply, Puraply Wound Matrix, Cygnus Dual |
| Incyte Corporation | $219.84 | 2021-2024 | Opzelura |
| Pfizer INC. | $208.53 | 2019-2025 | |
| Amgen INC. | $166.73 | 2019-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $141.96 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.72 | 2022-2025 | Spevigo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Mayne Pharma Commercial LLC | $85.89 | 2019 | |
| Strata Skin Sciences, INC. | $51.16 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $34.09 | 2023 | |
| Janssen Scientific Affairs, LLC | $26.40 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.81 | 2025 | |
| Dusa Pharmaceuticals, INC. | $20.39 | 2019 | |
| Dermira, INC. | $19.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.51 | 2019 | |
| Smith+Nephew, INC. | $16.46 | 2022 | |
| Fresenius Kabi USA, LLC | $16.45 | 2024 | Idacio |
| Bioventus LLC | $12.22 | 2022 | |
| Grt US Holding, INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stricker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.